New antibiotics to tackle multidrug resistant bacteria are much needed. Chantal Morel and Elias Mossialos show how financial incentives might be used to persuade drug companies to develop them
No takes yet. Share an insight, caveat, or question.
Morel et al. (2010) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: